Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Oncogenes promote uncontrolled cell growth and resistance to cancer therapies through gain-of-function mutations.
• Inactivating mutations in tumor suppressor genes like P53 and RB contribute to therapy resistance and create conditions favorable for viral infection.
• Oncogenes can interfere with cellular antiviral defenses, such as the protein kinase R (PKR), which normally halts viral replication.

Purpose of the Study:

• To review the dual role of oncogenes in cancer therapy resistance and oncolytic virotherapy.
• To explore how oncogene-induced alterations in cellular signaling and antiviral pathways impact treatment outcomes.
• To highlight the potential of oncolytic viruses as a targeted cancer treatment modality leveraging oncogenic pathways.

Main Methods:

• Literature review of studies on oncogenes, tumor suppressor genes, and oncolytic viruses.
• Analysis of molecular mechanisms underlying therapy resistance and viral oncolysis.
• Synthesis of findings on the interaction between oncogenic pathways and viral replication.

Main Results:

• Overexpressed oncogenes contribute to resistance against conventional and targeted cancer therapies.
• Oncogenes create a pro-viral environment within tumor cells by inactivating tumor suppressors and inhibiting PKR-mediated antiviral responses.
• This inhibition of PKR allows oncolytic viruses to replicate efficiently and induce tumor cell death.

Conclusions:

• Oncogenes represent a critical vulnerability that can be exploited for effective oncolytic virotherapy.
• Targeting oncogenic pathways offers a promising strategy to overcome therapeutic resistance and enhance cancer treatment.
• Oncolytic viruses demonstrate potential as a targeted therapy that specifically infects and eliminates cancer cells with oncogenic alterations.